Experienced in Childhood Iron Deficiency Anemia

Dr. Alan H. Bryce

Hematology Oncology | Oncology | Hematology
City Of Hope Medical Group Of Arizona LLC
14200 W Celebrate Life Way, 
Goodyear, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Childhood Iron Deficiency Anemia
City Of Hope Medical Group Of Arizona LLC
14200 W Celebrate Life Way, 
Goodyear, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alan Bryce is a Hematologist Oncology specialist and an Oncologist in Goodyear, Arizona. Dr. Bryce is rated as an Experienced provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Melanoma, and Urothelial Cancer. Dr. Bryce is currently accepting new patients.

His clinical research consists of co-authoring 124 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in MN
Hospital Affiliations
Western Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL GROUP OF ARIZONA LLC
14200 W Celebrate Life Way, Goodyear, AZ 85338

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Study Phase: Phase 1/Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
Enrollment Status: Completed
Publish Date: November 12, 2024
Intervention Type: Other, Drug
Study Drug: Camostat mesilate
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Enrollment Status: Active_not_recruiting
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 2
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drugs: Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Study Phase: Phase 2
A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Biological, Drug
Study Drugs: PT-112, Avelumab
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma
Enrollment Status: Completed
Publish Date: January 02, 2020
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

124 Total Publications

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 25, 2025
Similar Doctors
Distinguished in Childhood Iron Deficiency Anemia
Dr. Parmjeet K. Banghar
Hematology Oncology | Hematology | Oncology
Distinguished in Childhood Iron Deficiency Anemia
Dr. Parmjeet K. Banghar
Hematology Oncology | Hematology | Oncology

Honorhealth Ambulatory

19636 N 27th Ave, Suite 201, 
Phoenix, AZ 
 (20.3 miles away)
623-516-4400
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients
Offers Telehealth

Parmjeet Banghar is a Hematologist Oncology specialist and a Hematologist in Phoenix, Arizona. Dr. Banghar is rated as a Distinguished provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Anal Cancer, Childhood Iron Deficiency Anemia, Familial Colorectal Cancer, and Thrombocytopenia. Dr. Banghar is currently accepting new patients.

Distinguished in Childhood Iron Deficiency Anemia
Dr. Brendan F. Curley
Hematology Oncology | Hematology | Oncology
Distinguished in Childhood Iron Deficiency Anemia
Dr. Brendan F. Curley
Hematology Oncology | Hematology | Oncology

Honorhealth Ambulatory

20745 N Scottsdale Rd, Suite 120, 
Scottsdale, AZ 
 (29.6 miles away)
480-882-7510
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brendan Curley is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Curley is rated as a Distinguished provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Childhood Iron Deficiency Anemia, and Inflammatory Breast Cancer. Dr. Curley is currently accepting new patients.

Distinguished in Childhood Iron Deficiency Anemia
Dr. Monique Chang
Hematology Oncology | Hematology | Oncology
Distinguished in Childhood Iron Deficiency Anemia
Dr. Monique Chang
Hematology Oncology | Hematology | Oncology

Bhsm Rehabilitation LLC

10165 E Hampton Ave, Suite 111, 
Mesa, AZ 
 (43.7 miles away)
480-354-5424
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Monique Chang is a Hematologist Oncology specialist and a Hematologist in Mesa, Arizona. Dr. Chang is rated as a Distinguished provider by MediFind in the treatment of Childhood Iron Deficiency Anemia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Ovarian Carcinosarcoma, and Virilizing Ovarian Tumor. Dr. Chang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bryce's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 70 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile